These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39116881)

  • 1. Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.
    Raina K; Forbes CD; Stronk R; Rappi JP; Eastman KJ; Zaware N; Yu X; Li H; Bhardwaj A; Gerritz SW; Forgione M; Hundt A; King MP; Posner ZM; Correia AD; McGovern A; Puleo DE; Chenard R; Mousseau JJ; Vergara JI; Garvin E; Macaluso J; Martin M; Bassoli K; Jones K; Garcia M; Howard K; Yaggi M; Smith LM; Chen JM; Mayfield AB; De Leon CA; Hines J; Kayser-Bricker KJ; Crews CM
    Cell Chem Biol; 2024 Aug; 31(8):1490-1502.e42. PubMed ID: 39116881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively.
    Raina K; Forbes CD; Stronk R; Rappi JP; Eastman KJ; Gerritz SW; Yu X; Li H; Bhardwaj A; Forgione M; Hundt A; King MP; Posner ZM; Denny A; McGovern A; Puleo DE; Garvin E; Chenard R; Zaware N; Mousseau JJ; Macaluso J; Martin M; Bassoli K; Jones K; Garcia M; Howard K; Smith LM; Chen JM; De Leon CA; Hines J; Kayser-Bricker KJ; Crews CM
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors for targeting polo-like kinase 1.
    Kolosenko I; Palm-Apergi C
    Future Med Chem; 2020 Aug; 12(16):1457-1460. PubMed ID: 32638616
    [No Abstract]   [Full Text] [Related]  

  • 6. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
    J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing polo-like kinase 1 inhibitors.
    Huang X; Xie Z; Liao C
    Future Med Chem; 2020 May; 12(10):869-871. PubMed ID: 32233804
    [No Abstract]   [Full Text] [Related]  

  • 12. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
    Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
    Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
    Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
    Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
    J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
    Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.
    Cheung AK; Ip JC; Lung HL; Wu JZ; Tsao SW; Lung ML
    Mol Cancer Ther; 2013 Aug; 12(8):1393-401. PubMed ID: 23686835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents.
    Li S; Zhang Y; Xu W
    Mini Rev Med Chem; 2013 Dec; 13(14):2014-25. PubMed ID: 24160708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.